Kyverna Operating Income from 2010 to 2026
| KYTX Stock | 9.07 0.41 4.73% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -128.3 M | Current Value -121.9 M | Quarterly Volatility 41.1 M |
Check Kyverna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kyverna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 18.4 M, Interest Income of 18.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 136, Dividend Yield of 0.0 or PTB Ratio of 0.46. Kyverna financial statements analysis is a perfect complement when working with Kyverna Therapeutics Valuation or Volatility modules.
Kyverna | Operating Income | Build AI portfolio with Kyverna Stock |
Latest Kyverna Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Kyverna Therapeutics Common over the last few years. Operating Income is the amount of profit realized from Kyverna Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Kyverna Therapeutics Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Kyverna Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kyverna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Kyverna Operating Income Regression Statistics
| Arithmetic Mean | (47,106,825) | |
| Coefficient Of Variation | (87.26) | |
| Mean Deviation | 31,394,438 | |
| Median | (26,346,000) | |
| Standard Deviation | 41,107,634 | |
| Sample Variance | 1689.8T | |
| Range | 116.3M | |
| R-Value | (0.71) | |
| Mean Square Error | 885.8T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (5,805,457) | |
| Total Sum of Squares | 27037.4T |
Kyverna Operating Income History
About Kyverna Therapeutics Financial Statements
Kyverna Therapeutics investors use historical fundamental indicators, such as Kyverna Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kyverna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -128.3 M | -121.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.